Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 2939658, 11 pages
http://dx.doi.org/10.1155/2016/2939658
Research Article

Doxycycline Inhibits IL-17-Stimulated MMP-9 Expression by Downregulating ERK1/2 Activation: Implications in Myogenic Differentiation

Laboratory for Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Dr. Subotića 4, 11129 Belgrade, Serbia

Received 18 August 2016; Accepted 12 October 2016

Academic Editor: Helen C. Steel

Copyright © 2016 Hristina Obradović et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ivanov and A. Lindén, “Interleukin-17 as a drug target in human disease,” Trends in Pharmacological Sciences, vol. 30, no. 2, pp. 95–103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Bettelli, M. Oukka, and V. K. Kuchroo, “T(H)-17 cells in the circle of immunity and autoimmunity,” Nature Immunology, vol. 8, no. 4, pp. 345–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Chevrel, G. Page, C. Granet, N. Streichenberger, A. Varennes, and P. Miossec, “Interleukin-17 increases the effects of IL-1β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis,” Journal of Neuroimmunology, vol. 137, no. 1-2, pp. 125–133, 2003. View at Google Scholar
  4. F. Shen and S. L. Gaffen, “Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy,” Cytokine, vol. 41, no. 2, pp. 92–104, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. S. L. Gaffen, “Structure and signalling in the IL-17 receptor family,” Nature Reviews Immunology, vol. 9, no. 8, pp. 556–567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. U. Spate and P. C. Schulze, “Proinflammatory cytokines and skeletal muscle,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 7, no. 3, pp. 265–269, 2004. View at Google Scholar
  7. Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, “Functional specialization of interleukin-17 family members,” Immunity, vol. 34, no. 2, pp. 149–162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Tournadre and P. Miossec, “Interleukin-17 in inflammatory myopathies,” Current Rheumatology Reports, vol. 14, no. 3, pp. 252–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. J. E. Morgan and T. A. Partridge, “Muscle satellite cells,” International Journal of Biochemistry and Cell Biology, vol. 35, no. 8, pp. 1151–1156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Carmeli, M. Moas, A. Z. Reznick, and R. Coleman, “Matrix metalloproteinases and skeletal muscle: a brief review,” Muscle and Nerve, vol. 29, no. 2, pp. 191–197, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Dahiya, S. Bhatnagar, S. M. Hindi et al., “Elevated levels of active matrix metalloproteinase-9 cause hypertrophy in skeletal muscle of normal and dystrophin-deficient mdx mice,” Human Molecular Genetics, vol. 20, no. 22, pp. 4345–4359, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Chen and Y. Li, “Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis,” Cell Adhesion & Migration, vol. 3, no. 4, pp. 337–341, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Li, A. Mittal, D. Y. Makonchuk, S. Bhatnagar, and A. Kumar, “Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy,” Human Molecular Genetics, vol. 18, no. 14, pp. 2584–2598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Stechmiller, L. Cowan, and G. Schultz, “The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds,” Biological Research for Nursing, vol. 11, no. 4, pp. 336–344, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Pereira, C. Y. Matsumura, E. Minatel, M. J. Marques, and H. S. Neto, “Understanding the beneficial effects of doxycycline on the dystrophic phenotype of the mdx mouse,” Muscle and Nerve, vol. 50, no. 2, pp. 283–286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Zimowska, K. H. Olszynski, M. Swierczynska, W. Streminska, and M. A. Ciemerych, “Decrease of MMP-9 activity improves soleus muscle regeneration,” Tissue Engineering Part A, vol. 18, no. 11-12, pp. 1183–1192, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Su, Z. Li, Y. Li et al., “Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects,” Investigative Ophthalmology and Visual Science, vol. 52, no. 12, pp. 9108–9115, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. B. Payne, L. M. Golub, J. A. Stoner et al., “The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial,” Journal of the American Dental Association, vol. 142, no. 3, pp. 262–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Kocić, J. F. Santibañez, A. Krstić et al., “Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1823, no. 4, pp. 838–849, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. F. Santibáñez, J. Guerrero, M. Quintanilla, A. Fabra, and J. Martínez, “Transforming growth factor-β1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes,” Biochemical and Biophysical Research Communications, vol. 296, no. 2, pp. 267–273, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. T.-S. Yeh, C.-C. Hsu, S.-C. Yang, M.-C. Hsu, and J.-F. Liu, “Angelica Sinensis promotes myotube hypertrophy through the PI3K/Akt/mTOR pathway,” BMC Complementary and Alternative Medicine, vol. 14, article 144, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. F. Santibáñez, J. Kocić, A. Fabra, A. Cano, and M. Quintanilla, “Rac1 modulates TGF-β1-mediated epithelial cell plasticity and MMP9 production in transformed keratinocytes,” FEBS Letters, vol. 584, no. 11, pp. 2305–2310, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Gutierrez-Martin, F. J. Martin-Romero, and F. Henao, “Store-operated calcium entry in differentiated C2C12 skeletal muscle cells,” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1711, no. 1, pp. 33–40, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. Q. Xu and Z. Wu, “The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells,” Journal of Biological Chemistry, vol. 275, no. 47, pp. 36750–36757, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Brunet, G. Pagès, and J. Pouysségur, “Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts,” Oncogene, vol. 9, no. 11, pp. 3379–3387, 1994. View at Google Scholar · View at Scopus
  26. T. H. Vu and Z. Werb, “Matrix metalloproteinases: effectors of development and normal physiology,” Genes and Development, vol. 14, no. 17, pp. 2123–2133, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-S. Kim, L. Luo, S. C. Pflugfelder, and D.-Q. Li, “Doxycycline inhibits TGF-β1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells,” Investigative Ophthalmology and Visual Science, vol. 46, no. 3, pp. 840–848, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Philippou, M. Maridaki, and M. Koutsilieris, “The role of urokinase-type plasminogen activator (uPA) and transforming growth factor beta 1 (TGFbeta1) in muscle regeneration,” In Vivo, vol. 22, no. 6, pp. 735–750, 2008. View at Google Scholar · View at Scopus
  29. S. B. P. Chargé and M. A. Rudnicki, “Cellular and molecular regulation of muscle regeneration,” Physiological Reviews, vol. 84, no. 1, pp. 209–238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Kami, M. Masuhara, H. Kashiba, Y. Kawai, K. Noguchi, and E. Senba, “Changes of vinculin and extracellular matrix components following blunt trauma to rat skeletal muscle,” Medicine and Science in Sports and Exercise, vol. 25, no. 7, pp. 832–840, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. H. S. Alameddine, “Matrix metalloproteinases in skeletal muscles: friends or foes?” Neurobiology of Disease, vol. 48, no. 3, pp. 508–518, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Yan and D. D. Boyd, “Regulation of matrix metalloproteinase gene expression,” Journal of Cellular Physiology, vol. 211, no. 1, pp. 19–26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. A. K. Srivastava, X. Qin, N. Wedhas et al., “Tumor necrosis factor-∥augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-β-activated kinase 1 (TAK1)-dependent signaling pathway,” Journal of Biological Chemistry, vol. 282, no. 48, pp. 35113–35124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. L. M. Golub, H. M. Lee, M. E. Ryan, W. V. Giannobile, J. Payne, and T. Sorsa, “Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms,” Advances in Dental Research, vol. 12, no. 2, pp. 12–26, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. M. M. Castro, A. D. Kandasamy, N. Youssef, and R. Schulz, “Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases,” Pharmacological Research, vol. 64, no. 6, pp. 551–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. A. N. Sapadin and R. Fleischmajer, “Tetracyclines: nonantibiotic properties and their clinical implications,” Journal of the American Academy of Dermatology, vol. 54, no. 2, pp. 258–265, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. C. S. De Paiva, R. M. Corrales, A. L. Villarreal et al., “Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye,” Experimental Eye Research, vol. 83, no. 3, pp. 526–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Al-Shanti and C. E. Stewart, “PD98059 enhances C2 myoblast differentiation through p38 MAPK activation: a novel role for PD98059,” Journal of Endocrinology, vol. 198, no. 1, pp. 243–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Kherif, C. Lafuma, M. Dehaupas et al., “Expression of matrix metalloproteinases 2 and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx muscles,” Developmental Biology, vol. 205, no. 1, pp. 158–170, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Lluri and D. M. Jaworski, “Regulation of TIMP-2, MT1-MMP, and MMP-2 expression during C2C12 differentiation,” Muscle & Nerve, vol. 32, no. 4, pp. 492–499, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Kocić, J. F. Santibañez, A. Krstić, S. Mojsilović, V. Ilić, and D. Bugarski, “Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 2, pp. 464–475, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. S. M. Hindi, J. Shin, Y. Ogura, H. Li, and A. Kumar, “Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice,” PLoS ONE, vol. 8, no. 8, Article ID e72121, 2013. View at Publisher · View at Google Scholar · View at Scopus